Related Experiment Video
Updated: Jan 7, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Immune Checkpoint Inhibitor Therapy in Hormone Receptor-Positive Breast Cancer
David Lin1, Jin Sun Lee Bitar1, Isabella Ma1
1Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Abstract:
Recent progress in immunotherapy has led to the routine use of immune checkpoint inhibitors (ICIs) in TNBC therapy and significant improvement in clinical outcomes. Incorporation of ICI into HR+/HER2- or HER2+ breast cancer has been hindered by its poor immunogenicity, and many novel combination strategies aim to convert immune cold tumors into immune hot tumors and increase the immunogenicity of HR+/HER2- breast cancer. A few recent clinical trials have shown its potential promise in high-risk HR+/HER2- early-stage breast cancer, but there is insufficient evidence to support routine use of immunotherapy in HR+ breast cancer, and longer-term follow-up is required to understand its impact on survival. This review presents an overview of immunotherapies currently under clinical development and updated key results from clinical trials, with a focus on HR+/HER2- breast cacner.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Inhibition of Cdk Activity
Mitogens and the Cell Cycle